Biodistribution and Targeting of Anti-5T4 Antibody–Drug Conjugate Using Fluorescence Molecular Tomography
- 1 October 2016
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 15 (10) , 2530-2540
Abstract
Understanding a drug's whole-body biodistribution and tumor targeting can provide important information regarding efficacy, safety, and dosing parameters. Current methods to evaluate biodistribution include in vivo imaging technologies like positron electron tomography and single-photon emission computed tomography or ex vivo quantitation of drug concentrations in tissues using autoradiography and standard biochemical assays. These methods use radioactive compounds or are cumbersome and do not give whole-body information. Here, for the first time, we show the utility of fluorescence molecular tomography (FMT) imaging to determine the biodistribution and targeting of an antibody–drug conjugate (ADC). An anti–5T4-antibody (5T4-Ab) and 5T4-ADC were conjugated with a near-infrared (NIR) fluorophore VivoTag 680XL (VT680). Both conjugated compounds were stable as determined by SEC-HPLC and plasma stability studies. Flow cytometry and fluorescence microscopy studies showed that VT680-conjugated 5T4-ADC specifically bound 5T4-expressing cells in vitro and also exhibited a similar cytotoxicity profile as the unconjugated 5T4-ADC. In vivo biodistribution and tumor targeting in an H1975 subcutaneous xenograft model demonstrated no significant differences between accumulation of VT680-conjugated 5T4-Ab or 5T4-ADC in either normal tissues or tumor. In addition, quantitation of heart signal from FMT imaging showed good correlation with the plasma pharmacokinetic profile suggesting that it (heart FMT imaging) may be a surrogate for plasma drug clearance. These results demonstrate that conjugation of VT680 to 5T4-Ab or 5T4-ADC does not change the behavior of native biologic, and FMT imaging can be a useful tool to understand biodistribution and tumor-targeting kinetics of antibodies, ADCs, and other biologics. Mol Cancer Ther; 15(10); 2530–40. ©2016 AACR.Keywords
All Related Versions
This publication has 26 references indexed in Scilit:
- Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating CellsMolecular Cancer Therapeutics, 2013
- Tissue Distribution Studies of Protein Therapeutics Using Molecular Probes: Molecular ImagingThe AAPS Journal, 2012
- Quantitative Whole Body Biodistribution of Fluorescent-Labeled Agents by Non-Invasive Tomographic ImagingPLOS ONE, 2011
- Assessing Antibody Pharmacokinetics in Mice with In Vivo ImagingThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of DiseaseChemical Reviews, 2010
- Hybrid PET-optical imaging using targeted probesProceedings of the National Academy of Sciences, 2010
- Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and DiseaseThe AAPS Journal, 2009
- Hybrid In Vivo FMT-CT Imaging of Protease Activity in Atherosclerosis With Customized NanosensorsArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- In vivo molecular imaging: the inside jobNature Methods, 2009
- “Of mice and men”European Journal of Cancer, 2004